Cardiac Sarcoidosis Multi-Center Prospective Cohort (CHASM-CS)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT01477359|
Recruitment Status : Recruiting
First Posted : November 22, 2011
Last Update Posted : November 22, 2017
Recent data has shown that sarcoidosis, presenting initially with cardiac manifestations (CS) of either conduction system disease or cardiomyopathy and sustained VT, is not uncommon. A Canadian physician survey found that most physicians do not investigate for CS as a possibility in these situations. Thus many patients with clinically important CS are going un-diagnosed. A study from Finland showed that missing the diagnosis of CS in these patients' leads to significant mortality and morbidity.
There are no published clinical consensus guidelines on treatment of CS. Corticosteroid therapy is advocated by most experts. This is based on very modest data from small retrospective observational studies using variable definitions of clinical response. The effect of corticosteroid treatment on the clinical course of CS has not been studied in prospective studies and will be one of the aims of this project. Recent physician surveys regarding CS, in Canada and the US, found that current clinical practice varies widely. The 2008 American College of Cardiology/American Heart Association/Heart Rhythm society guidelines recommend implantation of a defibrillator (Class IIa recommendation) to prevent sudden cardiac death. The most recent Canadian device therapy guidelines do not mention CS.
A multi-center collaborative approach to study CS is greatly needed." The investigators propose exactly that i.e. a multi-center prospective cohort to start to answer clinical questions. The investigators have formed the CANADIAN CARDIAC SARCOIDOSIS RESEARCH GROUP. The group includes respirologists with an interest in sarcoidosis, cardiac electrophysiologists, cardiac imaging specialists with extensive experience in imaging of sarcoidosis and biostatisticians. The research will be in two phases; a registry of current diagnostic approaches, treatment and prognosis, and a randomized clinical trial of the effect of corticosteroid treatment on the clinical course of cardiac sarcoidosis.
|Condition or disease|
Baseline assessment of Clinically Manifest CS patients consists of: history, echocardiogram, ECG, chest CT scan, FDG-PET scan, blood for biomarkers within 2 months of the PET scan, cardiac MRI and possibly a signal average ECG and biopsy (encouraged-either endomyocardial or extra-cardiac).
Follow-up and clinical management of clinically manifest patients diagnosed with CS will occur at 3-6 months with a repeat FDG-PET scan and blood biomarkers. Follow-up will then be annually with an echo and ECG. Treatment with steroids/immunosuppressants and device therapy will be at the discretion of the treating physician.
Baseline assessment of patients diagnosed with extra-cardiac sarcoidosis and being screened for CS consists of: history, echocardiogram, ECG, holter, chest CT scan, biopsy, and cardiac MRI (CMR). If the CMR is suggestive of CS the patient will be have a FDG-PET scan done and be followed as a Clinically Silent patient. They will be contacted every 2 years. If the CMR is negative the patient will be followed as a extra-cardiac sarcoidosis patient with no evidence of CS and be in the control group. They will be contacted at 5 years and at the time of study completion.
All patients will be followed until the last patient recruited has been followed for 4 years.
The occurrence of the primary and secondary outcomes will be assessed in treated and untreated patients.
There will be 2 imaging core labs. The PET core lab will be located at UOHI under the direction of Dr. Robert Beanlands. The CMR core lab will be under the direction of Dr. Mathias Friedrich (McGill University). All scans will be read in the core labs by physicians who are blinded to the clinical details of the patients.
The Biomarker core lab will be at The University of Ottawa Heart Institute under the leadership of Dr P Liu.
|Study Type :||Observational|
|Estimated Enrollment :||1500 participants|
|Official Title:||Cardiac Sarcoidosis Multi-Center Prospective Cohort Study|
|Study Start Date :||August 2012|
|Estimated Primary Completion Date :||December 2025|
|Estimated Study Completion Date :||December 2025|
CS screened as underlying etiology
- Clinically Manifest Patients [ Time Frame: On active therapy for 6 months ]
"Clinically improved" if they are alive and not had a heart transplant and have not had heart failure hospitalization and no sustained VT/VF and meet one or more of following
(i) No sustained VT (if presented with sustained VT) (ii) Improvement in LV function (defined as 10% decrease in LV end systolic volume or 5% absolute increase in LVEF) (iii) Resolution of conduction system disease (if presented with sustained heart block)
failure hospitalization and have not had sustained VT and one or both of: a. LV function improvement (defined as 10% decrease in LV end systolic volume) b. Resolution of conduction system disease.
- Clinically Silent and Control Patients [ Time Frame: 9 years ]Cardiac death or cardiac transplantation or sustained VT/VF or sustained second or third degree AV block or development of clinical congestive heart failure (with documented LVEF < 50%).
- total mortality [ Time Frame: 6 months and 60 months ]
- cardiovascular mortality [ Time Frame: 6 months and 60 months ]
- heart failure hospitalization [ Time Frame: 6 months and 60 months ]
- change in LVEF from baseline [ Time Frame: 6 months and 60 months ]
- change in disease activity as assessed by PET imaging [ Time Frame: 6 months and 60 months ]comparing pre-treatment to 6 month scans
- Atrial Fibrillation burden [ Time Frame: 6 months and 60 months ]from defibrillator diagnostics
- Ventricular arrhythmia burden [ Time Frame: 6 months and 60 months ]from defibrillator diagnostics
- % of ventricular pacing [ Time Frame: 6 months and 60 months ]
Biospecimen Retention: Samples With DNA
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01477359
|Contact: Karen MacDonald, RN, BPE||613-696-7000 ext firstname.lastname@example.org|
|Contact: David Birnie, MDemail@example.com|
|Libin Cardiovascular Institute of Alberta||Recruiting|
|Calgary, Alberta, Canada, T2N 2T9|
|Contact: Russell Quinn, MD|
|Principal Investigator: Russell Quinn, MD|
|University of Alberta Hospital||Recruiting|
|Edmonton, Alberta, Canada, T6G 2B7|
|Contact: Tomascz Hruczkowski, MD|
|Principal Investigator: Tomascz Hruczkowski, MD|
|Canada, British Columbia|
|St. Paul's Hospital||Recruiting|
|Vancouver, British Columbia, Canada, V5Z 1M9|
|Contact: Shanta Chakrabarti, MD|
|Principal Investigator: Shanta Chakrabarti, MD|
|Hamilton Health Sciences Centre||Recruiting|
|Hamilton, Ontario, Canada, L8L 2X2|
|Contact: Jeff Healey, MD|
|Contact: Gerard Cox, MD|
|Principal Investigator: Jeff Healey, MD|
|London Health Sciences Centre||Recruiting|
|London, Ontario, Canada, N6A 5A5|
|Contact: Lorne Gula, MD|
|Principal Investigator: Lorne Gula, MD|
|University of Ottawa Heart Institute||Recruiting|
|Ottawa, Ontario, Canada, K1Y 4W7|
|Contact: Karen MacDonald, RN BPE 613-696-7000 ext 17077 firstname.lastname@example.org|
|Contact: Tammy Knight 613-696-7000 ext 19080 email@example.com|
|Principal Investigator: Pablo Nery, MD|
|St. Michael's Hospital||Recruiting|
|Toronto, Ontario, Canada, M5B 1W8|
|Contact: Paul Dorian, MD|
|Principal Investigator: Paul Dorian, MD|
|Toronto General Hospital||Recruiting|
|Toronto, Ontario, Canada, M5G 2C4|
|Contact: Andrew Ha, MD|
|Principal Investigator: Andrew Ha, MD|
|Montreal Heart Institute||Recruiting|
|Montreal, Quebec, Canada, H1T 1C8|
|Contact: Mario Talajic, MD|
|Principal Investigator: Mario Talajic, MD|
|Centre Hospitalier de l"Universite de Montreal-Hotel Dieu||Not yet recruiting|
|Montreal, Quebec, Canada, H2W 1T8|
|Contact: Julie Fleury, RN|
|Principal Investigator: Benoit Coutu, MD|
|McGill University Health Centre||Not yet recruiting|
|Montreal, Quebec, Canada, H3G 1A4|
|Contact: Fiorella Rafti|
|Principal Investigator: Vidal Essebag, MD|
|Hokkaido University Graduate School of Medicine||Recruiting|
|Contact: Hiroshi Ohira, MD|
|Principal Investigator: Hiroshi Ohira, MD|
|Principal Investigator:||David Birnie, MD||Ottawa Heart Institute Research Corporation|
|Principal Investigator:||Pablo Nery, MD||Ottawa Heart Institute Research Corporation|
|Principal Investigator:||Rob Beanlands, MD||Ottawa Heart Institute Research Corporation|